Professor Claude M. Wischik, co-founder and Executive Chairman of TauRx Therapeutics, along with colleagues at the University of Aberdeen, has devoted nearly 30 years to investigating the structure and role of tau tangles in the development of Alzheimer’s, frontotemporal dementia and other neurodegenerative diseases. Prof. Wischik discovered that the neurofibrillary tangles seen in Alzheimer’s disease are made of sub-units of the tau protein and he and his team have published extensively in the field.

Bentham, P., et al (2021) Long-Term Hydromethylthionine Treatment Is Associated with Delayed Clinical Onset and Slowing of Cerebral Atrophy in a Pre-Symptomatic P301S MAPT Mutation Carrier. Available at Journal of Alzheimer’s Disease.

Maina, M.B., et al (2021) Oxidative stress conditions result in trapping of PHF-core tau (297-391) intermediates. Available at: Cells

Schwab, K., et al (2021) Proteomic Analysis of Hydromethylthionine in the Line 66 Model of Frontotemporal Dementia Demonstrates Actions on
Tau-Dependent and Tau-Independent Networks, Available at Cells

Vuksanovic, V., et al (2021) Degeneration of basal and limbic networks is a core feature of behavioural variant frontotemporal dementia, Available at: Brain Communications